Precision Medicine - OHE

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

#image_title

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

Latest Research & Publications

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Important Aspects of Health Not Captured by EQ-5D: Views of the UK General Public

Uncertainty and Risk in HTA Decision Making

The Distribution of the EQ-5D-5L Index in Patient Populations

Improving Efficiency and Resource Allocation in Future Cancer Care

All Publications

Precision Medicine and Economics

Filter results by

OHE’s AMR consultation response

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

Filter results by

Share on Mastodon